The chemistry and biological activity of heterocycle-fused quinolinone derivatives: A review

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 397-408

  Shiro, Tomoya ^a   Fukaya, Takayuki ^a   Tobe, Masanori ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Heterocycles; Quinolin 4 one; Quinolinone

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ISOQUINOLINE DERIVATIVE; OXYGEN; QUINOLINE DERIVATIVE; HETEROCYCLIC COMPOUND; QUINOLONE DERIVATIVE;

BIOLOGICAL ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG SYNTHESIS; EC50; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; NONHUMAN; REVIEW; SUBSTITUTION REACTION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT;

ANIMALS; DRUG DISCOVERY; HETEROCYCLIC COMPOUNDS; HUMANS; QUINOLONES;

EID: 84937413813     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.12.004     Document Type: Review

References (77)

1. X.-F. Wu, H. Neumann, M. Beller, Synthesis of heterocycles via palladiumcatalyzed carbonylations, Chem. Rev. 113 (2013) 1-35;
2. M.R. Shaaban, R. El-Sayed, A.H.M. Elwahy, Construction of fused heterocycles by metal-mediater [2] cyclotrimerization of alkynes and/or nitriles, Tetrahedron 67 (2011) 6095-6130.
3. T. Shiro, H. Takahashi, K. Kakiguchi, Y. Inoue, K. Masuda, H. Nagata, M. Tobe, Synthesis and SAR study of imidazoquinolines as a novel structural class of microsomal prostaglandin E2 synthase-1 inhibitors, Bioorg. Med. Chem. Lett. 22 (2012) 285-288;
4. T. Shiro, K. Kakiguchi, H. Takahashi, H. Nagata, M. Tobe, Synthesis and biological evaluation of substituted imidazoquinoline derivatives as mPGES-1 inhibitors, Bioorg. Med. Chem 21 (2013) 2068-2078;
5. T. Shiro, K. Kakiguchi, H. Takahashi, H. Nagata, M. Tobe, 7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors, Bioorg. Med. Chem. 21 (2013) 2868-2878.
6. Y. Ikuma, H. Hochigai, H. Kimura, N. Nunami, T. Kobayashi, K. Uchiyama, Y. Furuta, M. Sakai, M. Horiguchi, Y. Masui, K. Okazaki, Y. Sato, H. Nakahira, Discovery of 3H-imidazo [4, 5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors, Bioorg. Med. Chem. 20 (2012) 5864-5883;
7. Y. Ikuma, H. Nakahira, Preparation of 2-aminosubstituted 3H-imidazo [4, 5-c]quinolin-4(5H)-ones by palladium-assisted internal biaryl coupling reaction, Tetrahedron 67 (2011) 9509-9517.
8. T. Ohashi, Y. Oguro, T. Tanaka, Z. Shiokawa, S. Shibata, Y. Sato, H. Yamakawa, H. Hattori, Y. Yamamoto, S. Kondo, M. Miyamoto, H. Tojo, A. Baba, S. Sasaki, Discovery of pyrrolo [3, 2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors, Bioorg. Med. Chem. 20 (2012) 5496-5506.
9. P. J. Conn, C. W. Lindsley, Hpkins, C. R. B. A. Chauder, R. D. Gogliotti, M. R. Wood, Substituted 1H-pyrrolo [3, 2-c]quinolin-4(5H)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4, PCT Int. Appl. WO2012154731, 15 November, 2012.
10. Y. Norimine, K. Hagiwara, Y. Suzuki, Y. Ishihara, N. Sato, Pyrazoloquinoline derivative, PCT Int. Appl WO2013051639, 11 April, 2013.
11. J. Asano, Y. Takano, J. Uda, T. Anraku, K. Fukuchi, Tricyclic compounds and addition salts thereof, PCT Int. Appl. WO0146190, 28 June, 2001.
12. F.R. Calabri, V. Colotta, D. Catarz, F. Varan, O. Lenzi, G. Filacchioni, C. Costagli, A. Galli, Synthesis and pharmacological studies at the Gly/NMDA, AMPA and Kainate receptors of new oxazolo [4, 5-c]quinolin-4-one derivatives bearing different substituents at position-2 and on the fused benzo ring, Eur. J. Med. Chem. 40 (2005) 897-907.
13. P.M. Fresneda, P. Molina, S. Delgado, A divergent approach to cryptotackieine and cryptosanguinolentine alkaloids, Tetrahedron Lett. 40 (1999) 7275-7278;
14. P.M. Fresneda, P. Molina, S. Delgado, A novel approach to the indoloquinoline alkaloids cryptotackieine and cryptosanguinolentine by application of cyclization of o-vinylsubstituted arylheterocumulenes, Tetrahedron 57 (2001) 6197-6202.
15. S. Hern-andez, I. Moreno, R. SanMartin, G. G-omez, M.T. Herrero, E. Domínguez, Toward safer processes for C-C biaryl bond construction: catalytic direct C-H arylation and tin-free radical coupling in the synthesis of pyrazolophenanthridines, J. Org. Chem. 75 (2010) 434-441.
16. P.G. Baraldi, M.A. Tabrizi, D. Preti, A. Bovero, F. Fruttarolo, R. Romagnoli, N.A. Zaid, A.R. Moorman, K. Varani, P.A. Borea, New 2-arylpyrazolo [4, 3-c] quinoline derivatives as potent and selective humanA3 adenosine receptor antagonists, J. Med. Chem. 48 (2005) 5001-5008.
17. H.T. Nagasawa, H.R. Gutmann, o-Methoxy derivatives of the carcinogen, N-2-fluorenylacetarmide. Potential latent biological arylating agents, J. Med. Chem. 9 (1966) 719-725;
18. I. Kubo, T. Kamikawa, Identification and efficient synthesis of 6-methoxy-2-benzoxazolinone (MBOA), an insect antifeedant, Experientia 39 (1983) 355.
19. S.X. Cai, Z.-L. Zhou, J.-C. Huang, E.R. Whittemore, Z.O. Egbuwoku, Y. Lu, J.E. Hawkinson, R.M. Woodward, E. Weber, J.F.W. Keana, Synthesis and structure-activity relationships of 1, 2, 3, 4-tetrahydroquinoline-2, 3, 4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site, J. Med. Chem. 39 (1996) 3248-3255.
20. S.X. Cai, Z.-L. Zhou, J.-C. Huang, E.R.Whittemore, Z.O. Egbuwoku, J.E. Hawkinson, R.M. Woodward, E. Weber, J.F.W. Keana, Structure-activity relationships of 4-hydroxy-3-nitroquinolin-2(1H)-ones as novel antagonists at the glycine site of N-methyl-D-aspartate receptors, J. Med. Chem. 39 (1996) 4682-4686.
21. C.D. Funk, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science 294 (2001) 1871-1875.
22. K. Watanabe, K. Kurihara, T. Suzuki, Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart, Biochem. Biophys. Acta 1438 (1999) 406-414;
23. T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, I. Kudo, Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis, J. Biol. Chem. 275 (2000) 32775-32782.
24. M. Murakami, H. Naraba, T. Tanioka, N. Semmyo, Y. Nakatani, F. Kojima, T. Ikeda, M. Fueki, A. Ueno, S. Oh-ishi, I. Kudo, Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2, J. Biol. Chem. 275 (2000) 32783-32793.
25. C.E. Trebino, J. Stock, C.P. Gibbons, B.M. Naiman, T.S. Wachtmann, J.P. Umland, K. Pandher, J.M. Lapointe, S. Saha, M.L. Roach, D. Carter, N.A. Thomas, B.A. Durtschi, J.D. McNeish, J.E. Hambor, P.J. Jakobsson, T.J. Carty, J.R. Perez, L.P. Audoly, Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9044-9049;
26. D. Kamei, K. Yamakawa, Y. Takegoshi, M. Mikami-Nakanishi, Y. Nakatani, S. Oh-ishi, H. Yasui, Y. Azuma, N. Hirasawa, K. Ohuchi, H. Kawaguchi, Y. Ishikawa, T. Ishii, S. Uematsu, S. Akira, M. Murakami, I. Kudo, Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1, J. Biol. Chem. 279 (2004) 33684-33695;
27. T. Mabuchi, H. Kojima, T. Abe, K. Takagi, M. Sakurai, Y. Ohmiya, S. Uematsu, S. Akira, K. Watanabe, S. Ito, Membrane-associated prostaglandin E synthase-1 is required for neuropathic pain, Neuroreport 15 (2004) 1395-1398.
28. D. Riendeau, R. Aspiotis, D. Ethier, Y. Gareau, E.L. Grimm, J. Guay, S. Guiral, H. Juteau, J.A. Mancini, N. M-ethot, J. Rubin, R.W. Friesen, Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886, Bioorg. Med. Chem. Lett. 15 (2005) 3352-3355;
29. B. Cote, L. Boulet, C. Brideau, D. Claveau, D. Ethier, R. Frenette, M. Gagnon, A. Giroux, J. Guay, S. Guiral, J. Mancini, E. Martins, F. Mass-e, N. M-ethot, D. Riendeau, J. Rubin, D. Xu, H. Yu, Y. Ducharme, R.W. Friesen, Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors, Bioorg. Med. Chem. Lett. 17 (2007) 6816-6820;
30. G.B. Arhancet, D.P. Walker, S. Metz, Y.M. Fobian, S.E. Heasley, J.S. Carter, J.R. Springer, D.E. Jones, M.J. Hayes, A.F. Shaffer, G.M. Jerome, M.T. Baratta, B. Zweifel, W.M. Moore, J.L. Masferrer, M.L. Vazquez, Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation, Bioorg. Med. Chem. Lett. 23 (2013) 1114-1119.
31. H.-J. Mest, R. Mentlein, Diabetologia 48 (2005) 616-620;
32. L.B. Knudsen, Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes, J. Med. Chem. 47 (2004) 4128-4134.
33. L. Farilla, H. Hui, C. Bertolotto, E. Kang, A. Bulotta, U. Di Mario, R. Perfetti, Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats, Endocrinology 143 (2002) 4397-4408;
34. M.K. Reimer, J.J. Holst, B. Ahren, Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice, Eur. J. Endocrinol. 146 (2002) 717-727;
35. A. Pospisilik, J. Martin, T. Doty, J.A. Ehses, N. Pamir, F.C. Lynn, S. Piteau, H.U. Demuth, C.H.S. McIntosh, R.A. Pederson, Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocininduced diabetic rats, Diabetes 52 (2003) 741-750.
36. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fischer, H. Huaibing, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R. Sinha Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, A.E. Weber, (2R)-4-oxo-4 [3-(trifluoromethyl)-5, 6-dihydro [1, 2, 4]triazolo [4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 48 (2005) 141-151;
37. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, T.E. Hughes, 1 [(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties, J. Med. Chem. 46 (2003) 2774-2789;
38. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, L.G. Hamann, Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 48 (2005) 5025-5037;
39. J. Feng, Z. Zhang, M.B. Wallace, J.A. Sttaford, S.W. Kaldor, D.B. Kassel, M. Navre, L. Shi, R.J. Skene, T. Asakawa, K. Takeuchi, R. Xu, D.R. Webb, S.L. Gwaltney, Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV, J. Med. Chem. 50 (2007) 2297-2300;
40. M. Eckhardt, E. Lanqkopf, M. Mark, M. Tadayyon, L. Thomas, H. Nar, W. Pfrengle, B. Guth, R. Lotz, P. Sieger, H. Fuchs, F. Himmelsbach, 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 50 (2007) 6450-6453.
41. M. Pasca di Magliano, M. Hebrok, Hedgehog signalling in cancer formation and maintenance, Nat. Rev. Cancer 3 (2003) 903-911;
42. P.A. Beachy, S.S. Karhadkar, D.M. Berman, Tissue repair and stem cell renewal in carcinogenesis, Nature 432 (2004) 324-331;
43. L. Lum, P.A. Beachy, The Hedgehog response network: sensors, switches, and routers, Science 304 (2004) 1755-1759.
44. D.M. Stone, M. Hynes, M. Armanini, T.A. Swanson, Q. Gu, R.L. Johnson, M.P. Scott, D. Pennica, A. Goddard, H. Phillips, M. Noll, J.E. Hooper, F. Sauvage, A. Rosenthal, The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog, Nature 384 (1996) 129-134.
45. J.P. Incardona, W. Gaffield, R.P. Kapur, H. Roelink, The teratogenic veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction, Development 125 (1998) 3553-3562;
46. R.L. Johnson, A.L. Rothman, J. Xie, L.V. Goodrich, J.W. Bare, J.M. Bonifas, A.G. Quinn, R.M. Myers, D.R. Cox, E.H. Epstein Jr., M.P. Scott, Human homolog of patched, a candidate gene for the basal cell nevus syndrome, Science 272 (1996) 1668-1671.
47. T. Mazumdar, J. DeVecchio, T. Shi, J. Jones, A. Agyeman, J.A. Houghton, Hedgehog signaling drives cellular survival in human colon carcinoma cells, Cancer Res. 71 (2011) 1092-1102;
48. A. Shaw, W. Bushman, Hedgehog signaling in the prostate, J. Urol. 177 (2007) 832-838;
49. S.P. Thayer, M.P. Magliano, P.W. Heiser, C.M. Nielsen, D.J. Roberts, G.Y. Lauwers, Y.P. Qi, S. Gysin, C.F. Castillo, V. Yajnik, B. Antoniu, M. McMahon, A.L. Warshaw, M. Hebrok, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis, Nature 425 (2003) 851-856.
50. Vismodegib Erivedge Prescription Information, Genetech USA, Inc, South San Francisco CA, 2012;
51. S. Pan, X. Wu, J. Jiang, W. Gao, Y. Wan, D. Cheng, D. Han, J. Liu, N.P. Englund, Y. Wang, S. Peukert, K. Miller-Moslin, J. Yuan, R. Guo, M. Matsumoto, A. Vattay, Y. Jiang, J. Tsao, F. Sun, A.C. Pferdekamper, S. Dodd, T. Tuntland, W. Maniara, J.F. Kelleher 3rd, Y.M. Yao, M. Warmuth, J. Williams, M. Dorsch, Discovery of NVP-LDE225, a potent and selective Smoothened antagonist, ACS Med. Chem. Lett. 1 (2010) 130-134;
52. M.J. Munchhof, Q. Li, A. Shavnya, G.V. Borzillo, T.L. Boyden, C.S. Jones, S.D. LaGreca, L. Martinez-Alsina, N. Patel, K. Pelletier, L.A. Reiter, M.D. Robbins, G.T. Tkalcevic, Discovery of PF-04449913, a potent and orally bioavailable inhibitor of Smoothened, ACS Med. Chem. Lett. 3 (2012) 106-111.
53. E.C. Hulme, N.J.M. Birdsall, N.J. Buckley, Muscarinic receptor subtypes, Annu. Rev. Pharmacol. Toxicol. 30 (1990) 633-673.
54. J. Wess, R.M. Eglen, D. Gautam, Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development, Nat. Rev. Drug Discov. 6 (2007) 721-733.
55. A.C. Kruse, B.K. Kobilka, D. Gautam, P.M. Sexton, A. Christopoulos, J. Wess, Muscarinic acetylcholine receptors: novel opportunities for drug development, Nat. Rev. Drug Discov. 13 (2014) 549-560.
56. A. Shekhar, W.Z. Potter, J. Lightfoot, J. Lienemann, S. Dub-e, C. Mallinckrodt, F.P. Bymaster, D.L. McKinzie, C.C. Felder, A. Shekhar, et al., Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia, Am. J. Psychiatry 165 (2008) 1033-1039.
57. M.L. Woolley, H.J. Carter, J.E. Gartlon, J.M. Watson, L.A. Dawson, Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice, Eur. J. Pharmacol. 603 (2009) 147-149.
58. P.J. Conn, A. Christopoulos, C.W. Lindsley, Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders, Nat. Rev. Drug Discov. 8 (2009) 41-54;
59. P.J. Conn, C.K. Jones, C.W. Lindsley, Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders, Trends Pharmacol. Sci. 30 (2009) 148-155.
60. V. Nawaratne, K. Leach, N. Suratman, R.E. Loiacono, C.C. Felder, B.N. Armbruster, B.L. Roth, P.M. Sexton, A. Christopoulos, New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug), Mol. Pharmacol. 74 (2008) 1119-1131.
61. U. Le, B.J. Melancon, T.M. Bridges, P.N. Vinson, T.J. Utley, A. Lamsal, A.L. Rodriguez, D. Venable, D.J. Sheffler, C.K. Jones, A.L. Blobaum, M.R. Wood, J.S. Daniels, P.J. Conn, C.M. Niswender, C.W. Lindsley, C.R. Hopkins, Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno [2, 3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia, Bioorg. Med. Chem. Lett. 23 (2013) 346-350.
62. J.M. Salovich, P.N. Vinson, D.J. Sheffler, A. Lamsal, T.J. Utley, A.L. Blobaum, T.M. Bridges, U. Le, C.K. Jones, M.R. Wood, J.S. Daniels, P.J. Conn, C.M. Niswender, C.W. Lindsley, C.R. Hopkins, Discovery of N-(4-methoxy-7-methylbenzo [d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor, Bioorg. Med. Chem. Lett. 22 (2012) 5084-5088.
63. J.A. Beavo, Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms, Phys. Rev. 75 (1995) 725-748.
64. F.S. Menniti, W.S. Faraci, C.J. Schmidt, Phosphodiesterases in the CNS: targets for drug development, Nat. Rev. Drug Discov. 5 (2006) 660-670;
65. D.H. Maurice, H. Ke, F. Ahmad, Y. Wang, J. Chung, V.C. Manganiello, Advances in targeting cyclic nucleotide phosphodiesterases, Nat. Rev. Drug Discov. 13 (2014) 290-314.
66. S.G. Andreeva, P. Dikkes, P.M. Epstein, P.A. Rosenberg, Expression of cGMPspecific phosphodiesterase 9A mRNA in the rat, Brain. J. Neurosci. 15 (2001) 9068-9076.
67. D.A. Fisher, J.F. Smith, J.S. Pillar, S.H.S. Denis, J.B. Cheng, Isolation and characterization of PDE9A, a novel human cGMP Specific phosphodiesterase, J. Biol. Chem. 25 (1998) 15559-15564.
68. Y.-F. Lu, E.R. Kandel, R.D. Hawkins, Nitric oxide signaling contributes to latephase LTP and CREB phosphorylation in the hippocampus, J. Neurosci. 19 (1999) 10250-10261.
69. F.J. van der Staay, K. Rutten, L.B. arfacker, J. DeVry, C. Erb, H. Heckroth, D. Karthaus, A. Tersteegen, M. van Kampen, A. Blokland, J. Prickaerts, K.G. Reymann, U.H. Schroder, M. Hendrix, The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents, Neuropharmacology 55 (2008) 908-918.
70. F. Wunder, A. Tersteegen, A. Rebmann, C. Erb, T. Fahrig, M. Hendrix, Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line, Mol. Pharmacol. 68 (2005) 1775-1781.
71. P.R. Verhoest, K.R. Fonseca, X. Hou, C. Proulx-LaFrance, M. Corman, C.J. Helal, M.M. Claffey, J.B. Tuttle, K.J. Coffman, S. Liu, F. Nelson, R.J. Kleiman, F.S. Menniti, C.J. Schmidt, M. Vanase-Frawley, S. Liras, Design and discovery of 6 [(3S, 4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo [3, 4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders, J. Med. Chem. 55 (2012) 9045-9054.
72. B.S. Meldrum, Glutamate as a neurotransmitter in the brain: review of physiology and pathology, J. Nutr. 130 (2000) 1007S-1015S.
73. J.C. Watkins, D.E. Jane, The glutamate story, Br. J. Pharmacol. 147 (2006) S100eS108.
74. H. Mattes, D. Carcache, H.O. Kalkman, M. Koller, a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside, J. Med. Chem. 53 (2010) 5367-5382.
75. S. Hibi, K. Ueno, S. Nagato, K. Kawano, K. Ito, Y. Norimine, O. Takenaka, T. Hanada, M. Yonaga, Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1, 2-dihydropyridin-3-yl)benzonitrile (Perampanel): a novel, noncompetitive aamino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist, J. Med. Chem. 55 (2012) 10584-10600.
76. J. Ohmori, M. Shimizu-Sasamata, M. Okada, S. Sakamoto, 8-(1H-Imidazol-1-yl)-7-nitro-4(5H)-imidazo [1, 2-a]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor, J. Med. Chem. 40 (1997) 2053-2063.
77. Y. Auberson, D. Carcache, A. Lerchner, J. Nozulak, 2, 4-Dioxo-1, 4-dihydro-2Hquinazoline-3-yl-sulfonamide derivatives, PCT Int. Appl WO2011144666, 24 November, 2011.